Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 23/7/2018
SIETES contiene 92430 citas

 
 
 1 a 20 de 331 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Anónimo. Acide valproïque: encéphalopathies hyperammoniémiques. Prescrire 2018;38:348. [Ref.ID 102656]
3.Enlace a cita original Cita con resumen
Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]
4.Enlace a cita original Cita con resumen
5. Cita con resumen
Hirschler B. UK bans Sanofi epilepsy drug without pregnancy prevention plan. Reuters Health News 2018:24 de abril. [Ref.ID 102553]
6. Cita con resumen
Pennel PB. Prescribing antiepileptic drugs to women of reproductive age. Lancet Neurol 2018:1. [Ref.ID 102517]
7. Cita con resumen
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F, for the EURAP study group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018:1. [Ref.ID 102516]
8.Tiene citas relacionadas Cita con resumen
Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]
9. Cita con resumen
Pennell PB. Antiepileptic drugs in pregnancy — Quick decisions with long-term consequences. JAMA Neurology 2018:1. [Ref.ID 102464]
10. Cita con resumen
Elkjær LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurology 2018:1. [Ref.ID 102463]
11.Tiene citas relacionadas Cita con resumen
Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]
12. Cita con resumen
Bjørk M, Riedel B, Spiqset O, Veiby G, Kolstad E, Daltveit AK, Gilhus NE. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs In utero. JAMA Neurology 2017:26 de diciembre. [Ref.ID 102193]
13. Cita con resumen
Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA 2017;318:1700-1. [Ref.ID 102140]
14. Cita con resumen
Anónimo. Acide valproïque et grossesse: évaluation des malformations en France. Prescrire 2017;37:513. [Ref.ID 102011]
15. Cita con resumen
Anónimo. Guanfacine et déficit de l'attention avec hyperactivité. Prescrire 2017;37:329-32. [Ref.ID 101647]
16. Cita con resumen
Anónimo. Malformations congénitales chez les enfants exposés in utero au valproate et aux autres traitements de l’épilepsie et des troubles bipolaires - Communiqué. Agence Nationale de Sécurité des Médicaments et des Produits de Santé 2017:20 de abril. [Ref.ID 101537]
17. Cita con resumen
Anónimo. Excès de poils d'origine médicamenteuse. Prescrire 2017;37:26. [Ref.ID 101367]
18. Cita con resumen
Anónimo. France establishes compensation fund for victims of epilepsy drug. DIA Daily 2016:1. [Ref.ID 100940]
19. Cita con resumen
Baftiu A, Landmark CJ, Rusten IR, Feet SA, Johannessen SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders - A pharmacoepidemiological study and clinical implications. Eur J Clin Pharmacol 2016;72:1245-54. [Ref.ID 100799]
20. Cita con resumen
Casassus B. Drug scandals in France: have the lessons been learnt?. Lancet 2016;388:550-2. [Ref.ID 100574]
Seleccionar todas
 
 1 a 20 de 331 siguiente >>